anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject agent capable of enhancing analgesic action, shortening developing time of action, exhibiting persistency and recovering in proper period by combinedly using dibucaine which is an active ingredient with a specific organic acid salt and a specific compound. SOLUTION: This therapeutic agent contains dibucaine or its physiologically permissible salt and a physiologically permissible salt of salicylic acid and calcium bromide. Hydrochloride is preferably used as the salt of dibucaine. Sodium salt of salicylic acid is preferably used as the salt of salicylic acid. Blend ratio of each component of the therapeutic agent for pain is 100-500 pts.wt. salicylic acid salt and 50-500 pts.wt. calcium bromide based on 100 pts.wt. dibucaine (salt). It is preferable that the therapeutic agent is a liquid agent having pH4-7. Pain and painful diseases include a pain, especially in lesion, e.g. myofascial pain, scapulohumeral periarthritis, sumptomatic neuralgia, subcutaneous pain, myalgia or arthralgia, accompanied by many locomotorium diseases.
PURPOSE: To obtain the subject medicinal formulation capable of economical oral administration, made up of a core comprising an active substance and common pharmaceutical auxiliary and a coating layer of hydrophobic substance such as fat or wax with specific acting condition containing a water-insoluble polymer. CONSTITUTION: This medicinal formulation is made up of a core comprising an active substance and common pharmaceutical auxiliary and a coating layer of hydrophobic substance such as fat or wax acting so as to delay release of the active substance, free from any physiological hazard, melting at 30-120 deg.C, pref. 40-100 deg.C, esp. 50-90 deg.C and containing 1/10-3 (pref. 1/5-2) pts.wt., per pt.wt. of the hydrophobic layer material, of a water-insoluble polymer (e.g. ethyl cellulose) other than a common preparation.
A method for preparing nicotine-containing agglomerates includes introducing a solid particulate into a fluid bed granulator, and introducing a binder solution into the fluid bed granulator such that the binder solution contacts the solid particulate. The solid particulate and/or binder solution may be introduced into the fluid bed granulator in parts, concurrently or in series. The binder solution includes a binder material and a solvent, which may include water. Introducing the binder solution into the fluid bed granulator may include spraying the binder solution into a fluid bed of the fluid bed granulator during circulation of the fluid bed and materials therein, such as the solid particulate. The fluid bed may further include a filler material and/or an additive. The filler material and/or the additive may be introduced into the fluid bed granulator prior to, concurrently with, or subsequent to the addition of the solid particulate and/or binder solution.
The invention discloses a kit for constructing a porcine nuclear transfer donor cell of an ABCA12 gene mutant harlequin ichthyosis model and application thereof. The present invention provides a polypeptide comprising SEQ ID NO:16, ABCA12-gRNA1, SEQ ID NO:17, ABCA12-gRNA4 and NCN protein. The invention also provides a method for preparing the recombinant porcine cells, which comprises the following steps: co-transfecting the ABCA12-gRNA1, the ABCA12-gRNA4 and the NCN protein to the pig cell to obtain a recombinant pig cell. The recombinant pig cell is a recombinant pig cell with mutant ABCA12 genes. The application of the kit is as follows: preparing a recombinant porcine cell; preparing spot-color ichthyosis model pigs; preparing a spot color ichthyosis cell model or a spot color ichthyosis tissue model or a spot color ichthyosis organ model. The invention has great application value for researching and developing the spot-color ichthyosis medicament and disclosing the pathogenesis of the spot-color ichthyosis.
1,158,346. Hair conditioner. CLAIROL Inc. 12 Aug., 1966 [27 Sept., 1965], No. 36287/66. Heading A5B. [Also in Division C3] A process for reconditioning damaged hair comprises polymerising - the hair a watersoluble polymerisable monomeric ethylenic compound having at least one acid group adjacent to an ethylenic carbon atom or salt thereof and bridging the polymeric chains so formed - the hair with an ionic bridging agent that reduces the water solubility of the polymeric chains. A composition for this process comprises the monomeric compound, a polymerisation catalyst and an ionic bridging agent. The hair may be treated with a swelling agent to facilitate the entrance of the monomeric compound. Polymerisation may be induced by the use of heat.
The present invention provides an antibody or antigen-binding fragment thereof that is capable of specifically binding to CD47. The invention also provides a recombinant oncolytic virus operably inserted into or comprising a gene coding sequence for an anti-CD 47 antibody or CD47 ligand. The recombinant oncolytic virus of the present invention, wherein the anti-CD 47 antibody comprises an Fc mutant with a330L/I332E mutation (ali antibody), i.e. the anti-CD 47 antibody is α CD47-Fc (ali). The invention provides a preparation method of the recombinant oncolytic virus. The invention also provides application of the recombinant oncolytic virus in preparation of anti-tumor drugs. The invention combines the gene therapy of tumor with the oncolytic effect, prepares the vaccinia virus Tiantan strain capable of efficiently expressing the alpha CD47-Fc (ALIE) gene, and obviously improves the tumor immunotherapy effect.
<P>PROBLEM TO BE SOLVED: To provide an aqueous composition having an excellent antibacterial, bacteriostatic, fungicidal and/or fungistatic effect even when the protamine content is small by synergistically improving antibacterial, antiseptic and preserving effects of protamine and boric acid by a simple method.  <P>SOLUTION: The antibacterial, bacteriostatic, fungicidal and/or fungistatic composition containing boric acid at high concentration relative to protamine can be further incorporated with polysorbates and/or edetic acids. Specifically, boric acid is contained in an amount of 6-630,000 pts.wt. per 1 pt.wt. of the protamine.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Obesity has been shown to be associated with initial onset of asthma in children and increased airway hyperresponsiveness in adults (1,2). An important aspect of these epidemiologic data is that the impact of obesity on asthma is much stronger in females than males. For example, the incidence of asthma after the age of 11 years is five- to sevenfold higher in female children who become obese versus those who remain lean, whereas no such relationship exists for males (3). Recent mouse models of obesity suggest that this condition enhances airway responses to ozone air pollution (4). These mice eat excessively due to a defect in the gene encoding leptin, a satiety hormone produced in adipocytes. Shore et al (4) showed that these leptin-deficient obese mice had greater airway hyperreactivity to i.v. methacholine following ozone exposure compared to lean, wild-type mice. Furthermore, administration of exogenous leptin (which is actually increased in the serum of obese individuals (4)) was shown to enhance ozone-induced cytokine and protein release into BAL fluid of lean, wild type mice (4). Reduced lung volumes and altered breathing patterns in the obese may also contribute to enhanced airway reactivity in these patients (5). Stretch of airway smooth muscle during tidal breathing and especially during deep breaths, i.e. sighs, acts as a potent bronchodilator that might ameliorate ozone-induced bronchoconstriction. The increased chest load associated with obesity may also diminish tidal breathing volumes and frequency of sighs during ozone exposure.
Background Bone marrow lesions (BMLs) are a known risk factor for incident knee osteoarthritis (OA), and deep learning (DL) methods can assist in automated segmentation and risk prediction. Purpose To develop and validate a DL model for quantifying tibiofemoral BML volume on MRI scans in knees without radiographic OA and to assess the association between longitudinal BML changes and incident knee OA. Materials and Methods This retrospective study included knee MRI scans from the Osteoarthritis Initiative prospective cohort (February 2004-October 2015). The DL model, developed between August and October 2023, segmented the tibiofemoral joint into 10 subregions and measured BML volume in each subregion. Baseline and 4-year follow-up MRI scans were analyzed. Knees without OA at baseline were categorized into three groups based on 4-year BML volume changes: BML-free, BML regression, and BML progression. The risk of developing radiographic and symptomatic OA over 9 years was compared among these groups. Results Included were 3869 non-OA knees in 2430 participants (mean age, 59.5 years ± 9.0 [SD]; female-to-male ratio, 1.3:1). At 4-year follow-up, 2216 knees remained BML-free, 1106 showed an increase in BML volume, and 547 showed a decrease in BML volume. BML progression was associated with a higher risk of developing radiographic knee OA compared with remaining BML-free (hazard ratio [HR] = 3.0; P < .001) or BML regression (HR = 2.0; P < .001). Knees with BML progression also had a higher risk of developing symptomatic OA compared with BML-free knees (HR = 1.3; P < .001). Larger volume changes in BML progression were associated with a higher risk of developing both radiographic OA (HR = 2.0; P < .001) and symptomatic OA (HR = 1.7; P < .001). In almost all subchondral plates, especially the medial femur and tibia, BML progression was associated with a higher risk of developing both radiographic and symptomatic OA compared with remaining BML-free. Conclusion Knees with BML progression, according to subregion and extent of volume changes, were associated with an increased risk of OA compared with BML-free knees and knees with BML regression, highlighting the potential utility of monitoring BML volume changes in evaluating interventions to prevent OA development. ClinicalTrials.gov Identifier: NCT00080171 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Said and Sakly in this issue.
Current therapeutic approaches for epilepsy primarily represent symptomatic treatments that suppress seizures, but have not been demonstrated to prevent epilepsy or modify disease progression. In recent years, there have been tremendous interest and effort by basic scientists and clinicians in epilepsy in developing disease-modifying or "antiepileptogenic" therapies. However, these efforts are hindered by a couple significant limitations: 1) difficulty in identifying an appropriate high-risk patient population in which a preventative approach is feasible and justifiable, and 2) lack of appropriate drug targets with antiepileptogenic properties. Tuberous Sclerosis Complex (TSC) is one of the most common genetic causes of epilepsy and a subset of TSC patients may represent a rational, feasible population to target with an antiepileptogenic approach for several reasons. First of all, some patients are diagnosed with TSC at a young age before the onset of epilepsy due to non-neurological findings - thus, it is feasible to identify these patients and initiate a potential antiepileptogenic treatment at an early stage of epileptogenesis. Second, these patients are at high risk for developing epilepsy (\~80%) in the future, including infantile spasms (\~35%), a particularly devastating type of childhood epilepsy with a poor prognosis - thus, initiating a therapy with potential side effects in a pre-symptomatic stage can likely be justified in TSC patients. Finally, the identification of the mTOR pathway in the pathophysiology of TSC suggests that mTOR inhibitors could have antiepileptogenic properties in TSC, as already supported by pre-clinical animal studies - thus, a rational mechanistically-based treatment potentially already exists and can be readily tested in TSC patients. However, there may be significant risks and side effects of mTOR inhibitors, especially during early childhood, such as chronic immunosuppression and theoretical effects on learning, growth, and development. Thus, before initiating an antiepileptogenic drug trial in TSC patients, it would be beneficial to obtain further evidence to optimize the selection criteria and treatment paradigms to maximize efficacy and minimize side effects of mTOR inhibitors.

The aim of this clinical trial is to determine whether EEGs during infancy is a reliable biomarker to identify TSC patients that will develop infantile spasms/epilepsy in the near future and thus are appropriate candidates for an antiepileptogenic drug trial.
Although the American Academy of Pediatrics (AAP) recommends universal early childhood developmental screening as part of routine well-child care, there have been many studies documenting that many pediatricians do not follow the AAP guidelines. One intervention that has the potential to improve care, especially for low-income families, is centralized, telephone-based developmental screening, and care coordination for families whose children have developmental or behavioral concerns. 2-1-1 Los Angeles developed such an intervention and this study aims to test its effectiveness, in partnership with a local community clinic, using a randomized, controlled study design. Investigators partnered with the Clinica Oscar A Romero, a federally-qualified health center in Los Angeles, serving predominantly low-income Latino families. Investigators hope to enroll up to 300 families in the study. Eligible families will have children ages 12 to 42 months of age who receive well-child care at the clinic. As investigators obtain informed consent and enroll families, they will randomize study participants into intervention and control groups. Intervention group families will be transferred to 211 Los Angeles to complete developmental screening over the phone, while control group families will go to their pediatricians for well-child care as usual.
AIMS: To investigate the current situation of mental psychology and quality of life (QoL) in patients with inflammatory bowel disease (IBD) in China, and analyze the influencing factors.
METHODS: A unified questionnaire was developed to collect clinical data on IBD patients from 42 hospitals in 22 provinces from September 2021 to May 2022. Multivariate Logistic regression analysis was conducted, and independent influencing factors were screened out to construct nomogram. The consistency index (C-index), receiver operating characteristic (ROC) curve, area under the ROC curve (AUC), calibration curve, and decision curve analysis (DCA) were used to evaluate the discrimination, accuracy, and clinical utility of the nomogram model.
RESULTS: A total of 2478 IBD patients were surveyed, including 1371 patients with ulcerative colitis (UC) and 1107 patients with Crohn's disease (CD). Among them, 25.5%, 29.7%, 60.2%, and 37.7% of IBD patients had anxiety, depression, sleep disturbance and poor QoL, respectively. The proportion of anxiety, depression, and poor QoL in UC patients was significantly higher than that in CD patients (all p < 0.05), but there was no difference in sleep disturbance between them (p = 0.737). Female, higher disease activity and the first visit were independent risk factors for anxiety, depression and sleep disturbance in IBD patients (all p < 0.05). The first visit, higher disease activity, abdominal pain and diarrhea symptoms, anxiety, depression and sleep disturbance were independent risk factors for the poor QoL of patients (all p < 0.05). The AUC value of the nomogram prediction model for predicting poor QoL was 0.773 (95% CI: 0.754-0.792). The calibration diagram of the model showed that the calibration curve fit well with the ideal curve, and DCA showed that the nomogram model could bring clinical benefits.
CONCLUSION: IBD patients have higher anxiety, depression, and sleep disturbance, which affect their QoL. The nomogram prediction model we constructed has high accuracy and performance when predicting QoL.
There were 84 MDD patients in the MDD group. 50 MDD subjects were enrolled at each acupoint for each test.
When infusing concentrated potassium solutions, including Potassium Chloride Injection, care must be taken to prevent paravenous administration or extravasation because such solutions may be associated with tissue damage, which may be severe and include vascular, nerve, and tendon damage, leading to surgical intervention, including amputation. Secondary complications including pulmonary embolism from thrombophlebitis have been reported as a consequence of tissue damage from potassium chloride. 

Administer intravenously only with a calibrated infusion device at a slow, controlled rate. (see DOSAGE AND ADMINISTRATION). Highest concentrations (400 mEq per L) should be exclusively administered via central intravenous route. Whenever possible, administration via a central route is recommended for all concentrations of Potassium Chloride Injection for thorough dilution by the blood stream and decreasing the risk of extravasation and to avoid pain and phlebitis associated with peripheral infusion. Correct placement of the catheter should be verified before administration.
A composition for the treatment of scours in animals or chronic respiratory disease in young chicks comprises a carboxylic cation exchange resin-adsorbate of neomycin in association with a therapeutically acceptable diluent or carrier.  The neomycin base content of the resin adsorbate is at least 100 micrograms per milligram of resin adsorbate, which may also contain up to 5% by weight of sodium ions.  The resin moiety may be amberlite IRC-50. The resin adsorbate may be suspended in syrups, viscous emulsions or semi-solid sucks.  It may be mixed with the animal feed or administered as a bolus.  Specifications 791,774 and 871,221 are referred to.
Long non-coding RNAs (lncRNAs) play an important role in the progression of gastric cancer (GC), but its specific regulatory mechanism remains to be further studied. We previously identified that lncRNA B3GALT5-AS1 was upregulated in GC serum. Here, we investigated the functions and molecular mechanisms of B3GALT5-AS1 in GC tumorigenesis. qRT-PCR was used to detect B3GALT5-AS1 expression in GC. EdU, CCK-8, and colony assays were utilized to assess the proliferation ability of B3GAL5-AS1, and transwell, tube formation assay were used to assess the invasion and metastasis ability. Mechanically, FISH and nuclear plasmolysis PCR identified the subcellular localization of B3GALT5-AS1. RIP and CHIP assays were used to analyse the regulation of B3GALT5-AS1 and B3GALT5. We observed that B3GALT5-AS1 was highly expressed in GC, and silencing B3GALT5-AS1 could inhibit the proliferation, invasion, and migratory capacities of GC. Additionally, B3GALT5-AS1 was bound to WDR5 and modulated the expression of B3GALT5 via regulating the ZEB1/β-catenin pathway. High-expressed B3AGLT5-AS1 promoted GC tumorigenesis and regulated B3GALT5 expression via recruiting WDR5. Our study is expected to provide a new idea for clinical diagnosis and treatment.
AIMS: In patients with heart failure (HF), concomitant sinus node dysfunction (SND) is an important predictor of mortality, yet its molecular underpinnings are poorly understood. Using proteomics, this study aimed to dissect the protein and phosphorylation remodelling within the sinus node in an animal model of HF with concurrent SND.
METHODS AND RESULTS: We acquired deep sinus node proteomes and phosphoproteomes in mice with heart failure and SND and report extensive remodelling. Intersecting the measured (phospho)proteome changes with human genomics pharmacovigilance data, highlighted downregulated proteins involved in electrical activity such as the pacemaker ion channel, Hcn4. We confirmed the importance of ion channel downregulation for sinus node physiology using computer modelling. Guided by the proteomics data, we hypothesized that an inflammatory response may drive the electrophysiological remodeling underlying SND in heart failure. In support of this, experimentally induced inflammation downregulated Hcn4 and slowed pacemaking in the isolated sinus node. From the proteomics data we identified proinflammatory cytokine-like protein galectin-3 as a potential target to mitigate the effect. Indeed, in vivo suppression of galectin-3 in the animal model of heart failure prevented SND.
CONCLUSION: Collectively, we outline the protein and phosphorylation remodeling of SND in heart failure, we highlight a role for inflammation in electrophysiological remodelling of the sinus node, and we present galectin-3 signalling as a target to ameliorate SND in heart failure.
The invention relates to a chinese medicine preparation for gastrointestinal diseases and preparation method thereof, belonging to Chinese medicine techinical domain. It is mainly composed of lindera reflexa, eggshell power, honey and appropriate adjuvants. The species, dosages, proportion with principal drug of the adjuvants are reasonable. The technics is feasible, and the quality is controllable. The preparation is gel, especially satisfactory for children and the elder, with good flavor and fine appearance. The invention enriches the formulation breeds to extend the range of users. The preparation is a new type preparation suitable for both the young and the old.
Gastric cancer (GC) is the fifth most common cause of cancer-related death worldwide. Early detection is crucial for improving survival rates and treatment outcomes. However, accurate GC-specific biomarkers remain unknown. This study aimed to identify the metabolic differences between intestinal metaplasia (IM) and GC to determine the pathways involved in GC. A metabolic analysis of IM and tissue samples from 37 patients with GC was conducted using ultra-performance liquid chromatography with tandem mass spectrometry. Overall, 665 and 278 significant features were identified in the aqueous and 278 organic phases, respectively, using false discovery rate analysis, which controls the expected proportion of false positives among the significant results. sPLS-DA revealed a clear separation between IM and GC samples. Steroid hormone biosynthesis, tryptophan metabolism, purine metabolism, and arginine and proline metabolism were the most significantly altered pathways. The intensity of 11 metabolites, including N1, N2-diacetylspermine, creatine riboside, and N-formylkynurenine, showed significant elevation in more advanced GC. Based on pathway enrichment analysis and cancer stage-specific alterations, we identified six potential candidates as diagnostic biomarkers: aldosterone, N-formylkynurenine, guanosine triphosphate, arginine, S-adenosylmethioninamine, and creatine riboside. These metabolic differences between IM and GC provide valuable insights into gastric carcinogenesis. Further validation is needed to develop noninvasive diagnostic tools and targeted therapies to improve the outcomes of patients with GC.